Protagonist Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Protagonist Therapeutics
PTGX Stock  USD 94.03  2.73  2.99%   
Protagonist Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Protagonist Therapeutics' valuation are provided below:
Gross Profit
46 M
Profit Margin
(2.83)
Market Capitalization
6 B
Enterprise Value Revenue
24.8388
Revenue
46 M
We have found one hundred twenty available trending fundamental ratios for Protagonist Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protagonist Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 5.2 B in 2026. Enterprise Value is likely to rise to about 5.1 B in 2026

Protagonist Therapeutics Total Revenue

61.8 Million

Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 4.1 M or Selling General Administrative of 23.1 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 9.48. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protagonist Stock
Check out the analysis of Protagonist Therapeutics Correlation against competitors.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Protagonist Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets701.6 M668.2 M236 M
Slightly volatile
Other Current Liabilities17.9 M28.3 M12.7 M
Slightly volatile
Total Current Liabilities31.6 M45.4 M22.4 M
Slightly volatile
Other Liabilities132.2 K139.2 K2 M
Very volatile
Property Plant And Equipment Net12.3 M11.7 M4.1 M
Slightly volatile
Accounts Payable5.6 M5.3 M2.1 M
Slightly volatile
Cash94.9 M128.4 M68.6 M
Slightly volatile
Non Current Assets Total95.1 M90.6 M23.5 M
Slightly volatile
Other Assets245.8 K258.8 K324.1 K
Pretty Stable
Cash And Short Term Investments595.7 M567.4 M196.2 M
Slightly volatile
Net Receivables203.5 M193.8 M35.5 M
Slightly volatile
Common Stock Shares Outstanding36.6 M63.6 M27 M
Slightly volatile
Short Term Investments460.9 M439 M125.2 M
Slightly volatile
Other Current Assets6.6 M10.2 M4.7 M
Slightly volatile
Other Stockholder Equity1.1 B1.1 B414.7 M
Slightly volatile
Total Liabilities39.2 M53.5 M28 M
Slightly volatile
Property Plant And Equipment Gross21 M20 M6.4 M
Slightly volatile
Total Current Assets606.5 M577.6 M212.4 M
Slightly volatile
Property Plant Equipment2.5 M1.8 M1.8 M
Slightly volatile
Non Currrent Assets Other82.9 M78.9 M9.7 M
Slightly volatile
Long Term Debt Total6.6 M11.3 M7 M
Slightly volatile
Capital Surpluse908.9 M865.6 M366.6 M
Slightly volatile
Current Deferred Revenue9.5 M9.6 M19.9 M
Slightly volatile
Net Invested Capital335.5 M614.7 M230.9 M
Slightly volatile
Net Working Capital308.5 M532.1 M211.3 M
Slightly volatile
Deferred Long Term Asset Charges526.4 K592.2 K646.4 K
Slightly volatile
Short Term Debt1.7 M2.3 M1.3 M
Slightly volatile
Short and Long Term Debt Total6.3 M10.3 M12.6 M
Slightly volatile
Capital Lease Obligations7.1 M10.3 M6.9 M
Very volatile

Protagonist Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.2 M1 M
Slightly volatile
Selling General Administrative23.1 M44.9 M16.6 M
Slightly volatile
Other Operating Expenses111.1 M204.1 M80 M
Slightly volatile
Research Development88.1 M159.3 M63.5 M
Slightly volatile
Total Operating Expenses111 M202.9 M80 M
Slightly volatile
Net Interest Income30.2 M28.8 M6.5 M
Slightly volatile
Interest Income30.2 M28.8 M6.6 M
Slightly volatile
Non Operating Income Net Other4.8 M4.6 M1.7 M
Slightly volatile
Reconciled Depreciation2.4 M1.3 M1.5 M
Slightly volatile

Protagonist Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation48.3 M46 M13.6 M
Slightly volatile
Begin Period Cash Flow84.1 M97.2 M60.9 M
Slightly volatile
Depreciation1.9 M1.3 M1.4 M
Slightly volatile
Capital Expenditures835.7 K1.6 M655.8 K
Slightly volatile
Total Cash From Financing Activities21.7 M22.9 M55.4 M
Slightly volatile
End Period Cash Flow95.1 M128.4 M68.8 M
Slightly volatile
Change To Netincome29.2 M27.8 M11.3 M
Slightly volatile
Exchange Rate Changes17.6 K19.8 K21.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13012177.7632
Pretty Stable
Days Sales Outstanding33.8835.6624670
Very volatile
Book Value Per Share5.139.66935.1467
Slightly volatile
Stock Based Compensation To Revenue0.950.99912.4932
Very volatile
Capex To Depreciation0.840.540.8473
Slightly volatile
EV To Sales11811869.2609
Pretty Stable
Payables Turnover0.180.210.2169
Pretty Stable
Sales General And Administrative To Revenue0.930.97474.6306
Very volatile
Research And Ddevelopement To Revenue3.293.461618.9893
Very volatile
Capex To Revenue0.03280.03460.2726
Very volatile
Cash Per Share5.148.92465.2114
Slightly volatile
Days Payables Outstanding1.7 K1.8 K1.7 K
Slightly volatile
Current Ratio6.8612.71048.1912
Slightly volatile
Tangible Book Value Per Share5.139.66935.1478
Slightly volatile
Receivables Turnover9.7210.234938.0762
Pretty Stable
Debt To Equity0.0160.01680.1316
Slightly volatile
Capex Per Share0.03530.0250.0367
Slightly volatile
Graham Net Net4.368.10964.3974
Slightly volatile
Revenue Per Share1.180.72381.3203
Pretty Stable
Interest Debt Per Share0.220.16240.4474
Slightly volatile
Debt To Assets0.03040.01540.0713
Slightly volatile
Graham Number26.5729.8932.6265
Slightly volatile
Short Term Coverage Ratios20.2122.7324.8151
Slightly volatile
Days Of Payables Outstanding1.7 K1.8 K1.7 K
Slightly volatile
Ebt Per Ebit1.10.81781.0473
Slightly volatile
Long Term Debt To Capitalization0.0880.09820.1072
Slightly volatile
Total Debt To Capitalization0.01570.01650.1095
Slightly volatile
Debt Equity Ratio0.0160.01680.1316
Slightly volatile
Quick Ratio6.9512.71048.2716
Slightly volatile
Net Income Per E B T0.81.00650.9751
Slightly volatile
Cash Ratio2.772.82544.2269
Slightly volatile
Days Of Sales Outstanding33.8835.6624670
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.090.97241.0107
Pretty Stable
Fixed Asset Turnover3.743.936717.8162
Slightly volatile
Debt Ratio0.03040.01540.0713
Slightly volatile
Price Sales Ratio13012177.7632
Pretty Stable
Asset Turnover0.130.06870.1428
Pretty Stable
Gross Profit Margin0.780.880.9565
Slightly volatile

Protagonist Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.2 B5 B1.2 B
Slightly volatile
Enterprise Value5.1 B4.9 B1.2 B
Slightly volatile

Protagonist Fundamental Market Drivers

Forward Price Earnings22.0264
Cash And Short Term Investments567.4 M

Protagonist Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.6 M9.5 M
Total Revenue46 M61.8 M
Cost Of Revenue1.2 M1.2 M
Stock Based Compensation To Revenue 1.00  0.95 
Sales General And Administrative To Revenue 0.97  0.93 
Research And Ddevelopement To Revenue 3.46  3.29 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.72  1.18 
Ebit Per Revenue(3.44)(3.61)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY